{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:13:00Z","timestamp":1793743980463,"version":"4.6.1"},"reference-count":33,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Several therapies have recently been licensed for the treatment of patients with moderately to severely active ulcerative colitis (UC). To provide comparative evidence of newly available treatments, Bayesian network meta-analyses were conducted to compare their relative efficacy and safety profiles in both the induction and maintenance phases.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A systematic literature review was conducted to identify the available literature on randomized controlled trials for advanced treatments (AT) of moderately to severely active UC. Bayesian network meta-analyses were used to synthesize evidence on prespecified efficacy and safety outcomes. Primary efficacy end points clinical response and clinical remission were measured at the end of induction and clinical response and clinical remission among induction phase responders were assessed at the end of the maintenance period. Efficacy outcomes were analyzed separately for AT-naive and -experienced populations. Safety outcomes included serious infections over the induction period, and serious infections among others over the maintenance period. Treat-through trial outcomes were adjusted to align with responder rerandomized trial outcomes.\n                    <jats:bold>Results:<\/jats:bold>\n                    The systematic review identified 58 relevant trials of which 28 met criteria for inclusion in the main analysis networks. At the end of the induction period, all treatments were efficacious against placebo for both AT-naive and AT-experienced populations. Upadacitinib 45\u00a0mg demonstrated a higher likelihood of clinical response and remission compared with other treatments. Adalimumab had less favorable performance over the induction period. Among induction phase responders, most treatments demonstrated similar efficacy at the end of the maintenance period. Tofacitinib 10\u00a0mg was more likely to achieve clinical response and remission than several other treatments in the AT-naive population. In the AT-experienced population, upadacitinib 30\u00a0mg demonstrated a higher likelihood of clinical response and remission compared with other treatments. The safety outcomes among treatments were similar.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study provides an updated comparison of treatments for moderately to severely active UC. Most treatments demonstrated comparable efficacy at the end of maintenance. The findings from this study can inform decision making in treatment choice for patients with moderately to severely active UC.\n                  <\/jats:p>","DOI":"10.57264\/cer-2024-0225","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T12:23:06Z","timestamp":1742214186000},"source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"first","affiliation":[{"name":"Department of Medicine &amp; Department of Epidemiology &amp; Biostatistics, Western University, London, ON, N6G 2M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5855-9873","authenticated-orcid":false,"given":"Tim","family":"Raine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Addenbrooke\u2019s Hospital, Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-6224","authenticated-orcid":false,"given":"Thomas P","family":"Leahy","sequence":"additional","affiliation":[{"name":"Putnam Associates LLC, Toronto, ON, M5V 3T5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-2659","authenticated-orcid":false,"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[{"name":"Putnam Associates LLC, New York, NY 10282, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7233-0933","authenticated-orcid":false,"given":"Karolina","family":"Wosik","sequence":"additional","affiliation":[{"name":"Pfizer Canada, Kirkland, QC, H9J 2M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT 06340, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0748","authenticated-orcid":false,"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT 06340, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY 10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Bartolome","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY 10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1572-0241.2006.01000.x","article-title":"Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies","volume":"102","author":"Jess T","year":"2007","unstructured":"Jess T, Gamborg M, Munkholm P, S\u00f8rensen TI. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am. J. Gastroenterol. 102(3), 609\u2013617 (2007).","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"e_1_3_8_4_2","first-page":"699","article-title":"Ulcerative colitis","volume":"15","author":"Adams S","year":"2013","unstructured":"Adams S, Bornemann P. Ulcerative colitis. Am. Fam. Physician 15(10), 699\u2013705 (2013).","journal-title":"Am. Fam. Physician"},{"key":"e_1_3_8_5_2","volume-title":"NICE Process and Methods Guides. Methods for the Development of NICE Public Health Guidance","author":"National Institute for Health and Care Excellence","year":"2012","unstructured":"National Institute for Health and Care Excellence. NICE Process and Methods Guides. Methods for the Development of NICE Public Health Guidance. National Institute for Health and Care Excellence (NICE), Royston, UK (2012)."},{"key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Brit. Med. J. 372, n71 (2021).","journal-title":"Brit. Med. J."},{"key":"e_1_3_8_7_2","volume-title":"Process and methods [PMG6]: The Guidelines Nanual","author":"National Institute for Health and Care Excellence","year":"2012","unstructured":"National Institute for Health and Care Excellence. Process and methods [PMG6]: The Guidelines Nanual. National Institute for Health and Care Excellence (NICE), Royston, UK (2012)."},{"issue":"26","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder KW","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N. Engl. J. Med. 317(26), 1625\u20131629 (1987).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_9_2","volume-title":"Technology appraisal guidance [TA547]: tofacitinib for previously treated active ulcerative colitis","author":"National Institute for Health and Care Excellence","year":"2018","unstructured":"National Institute for Health and Care Excellence. Technology appraisal guidance [TA547]: tofacitinib for previously treated active ulcerative colitis. National Institute for Health and Care Excellence (NICE), Royston, UK (2018)."},{"issue":"2","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11096-022-01509-1","article-title":"Comparative efficacy of advanced treatments in biologic-na\u00efve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis","volume":"45","author":"Lu X","year":"2023","unstructured":"Lu X, Jarrett J, Sadler S Comparative efficacy of advanced treatments in biologic-na\u00efve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis. Int. J. Clin. Pharm. 45(2), 330\u2013341 (2023).","journal-title":"Int. J. Clin. Pharm."},{"issue":"2","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis","volume":"5","author":"Panaccione R","year":"2023","unstructured":"Panaccione R, Collins EB, Melmed GY Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis 360 5(2), otad009 (2023).","journal-title":"Crohns Colitis 360"},{"key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS \u2013 a Bayesian modeling framework: concepts, structure and extensibility","volume":"10","author":"Lunn D","year":"2000","unstructured":"Lunn D, Thomas A, Best N, Spiegelhalter D. WinBUGS \u2013 a Bayesian modeling framework: concepts, structure and extensibility. Stat. Comput. 10, 325\u2013337 (2000).","journal-title":"Stat. Comput."},{"issue":"9","key":"e_1_3_8_13_2","first-page":"Cd011572","article-title":"Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis","volume":"9","author":"Jairath V","year":"2017","unstructured":"Jairath V, Zou GY, Parker CE Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst. Rev. 9(9), Cd011572 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman A","year":"1992","unstructured":"Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. Stat. Sci. 7(4), 457\u2013472 (1992).","journal-title":"Stat. Sci."},{"key":"e_1_3_8_15_2","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JP","year":"2019","unstructured":"Higgins JP, Thomas J, Chandler J Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons (2019)."},{"key":"e_1_3_8_16_2","unstructured":"Daly C Downing BC Welton NJ. A practical guide to inconsistency checks in Bayesian network meta-analysis. (2022). Available from: https:\/\/www.bristol.ac.uk\/media-library\/sites\/social-community-medicine\/documents\/mpes\/Guide%20to%20Checking%20for%20Inconsistency%20in%20NMA_TSU.pdf"},{"key":"e_1_3_8_17_2","unstructured":"European Medicines Agency. Humira: EPAR \u2013 Product Information Amsterdam Netherlands. (2024). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf"},{"key":"e_1_3_8_18_2","unstructured":"European Medicines Agency. Jyseleca: EPAR \u2013 Product Information Amsterdam Netherlands. (2024). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf"},{"key":"e_1_3_8_19_2","unstructured":"European Medicines Agency. Xeljanz: EPAR \u2013 Product Information Amsterdam Netherlands. (2025). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf"},{"key":"e_1_3_8_20_2","unstructured":"European Medicines Agency. Rinvoq: EPAR \u2013 Product Information Amsterdam Netherlands. (2025). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf"},{"issue":"8","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/phar.1785","article-title":"Safety profile of biologic drugs in the therapy of ulcerative colitis: a systematic review and network meta-analysis","volume":"36","author":"Mo\u0107ko P","year":"2016","unstructured":"Mo\u0107ko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of ulcerative colitis: a systematic review and network meta-analysis. Pharmacotherapy 36(8), 870\u2013879 (2016).","journal-title":"Pharmacotherapy"},{"issue":"7","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis","volume":"39","author":"Stidham RW","year":"2014","unstructured":"Stidham RW, Lee TC, Higgins PD Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 39(7), 660\u2013671 (2014).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"e000302","DOI":"10.1136\/bmjgast-2019-000302","article-title":"Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation","volume":"6","author":"Lohan C","year":"2019","unstructured":"Lohan C, Diamantopoulos A, LeReun C Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol. 6(1), e000302 (2019).","journal-title":"BMJ Open Gastroenterol."},{"issue":"6","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s11096-018-0743-4","article-title":"Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis","volume":"40","author":"Trigo-Vicente C","year":"2018","unstructured":"Trigo-Vicente C, Gimeno-Ballester V, Garc\u00eda-L\u00f3pez S, L\u00f3pez-Del Val A. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int. J. Clin. Pharm. 40(6), 1411\u20131419 (2018).","journal-title":"Int. J. Clin. Pharm."},{"issue":"7","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/jcpt.13622","article-title":"Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis","volume":"47","author":"Li Y","year":"2022","unstructured":"Li Y, Yao C, Xiong Q Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. J. Clin. Pharm. Ther. 47(7), 851\u2013859 (2022).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/03007995.2020.1716701","article-title":"Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"36","author":"Welty M","year":"2020","unstructured":"Welty M, Mesana L, Padhiar A Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr. Med. Res. Opin. 36(4), 595\u2013606 (2020).","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1586\/17474124.2015.1024657","article-title":"Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs","volume":"9","author":"Thorlund K","year":"2015","unstructured":"Thorlund K, Druyts E, Toor K, Mills EJ. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev. Gastroenterol. Hepatol. 9(5), 693\u2013700 (2015).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/MEG.0000000000002751","article-title":"Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis","volume":"36","author":"Rokkas T","year":"2024","unstructured":"Rokkas T, Gisbert JP, Ekmektzoglou K Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis. Eur. J. Gastroenterol. Hepatol. 36(5), 520\u2013533 (2024).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"10","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr NE","year":"2022","unstructured":"Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 71(10), 1976\u20131987 (2022).","journal-title":"Gut"},{"issue":"7","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association Evidence Synthesis","volume":"167","author":"Ananthakrishnan AN","year":"2024","unstructured":"Ananthakrishnan AN, Murad MH, Scott FI Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology 167(7), 1460\u20131482 (2024).","journal-title":"Gastroenterology"},{"issue":"2","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa JS","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 7(2), 161\u2013170 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"e_1_3_8_32_2","volume-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias S","year":"2011","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE), Royston, UK (2011)."},{"issue":"4","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano V","year":"2023","unstructured":"Solitano V, Facciorusso A, Jess T Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 21(4), 907\u2013921.e2 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"11","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2011.04507.x","article-title":"External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?","volume":"9","author":"Beyer-Westendorf J","year":"2011","unstructured":"Beyer-Westendorf J, B\u00fcller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J. Thromb. Haemost. 9(11), 2153\u20132158 (2011).","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"otab007","DOI":"10.1093\/crocol\/otab007","article-title":"Full, partial, and modified permutations of the Mayo Score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients","volume":"3","author":"Naegeli AN","year":"2021","unstructured":"Naegeli AN, Hunter T, Dong Y Full, partial, and modified permutations of the Mayo Score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients. Crohns Colitis 360 3(1), otab007 (2021).","journal-title":"Crohns Colitis 360"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:47:18Z","timestamp":1744778838000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.57264\/cer-2024-0225"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0225","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"e240225"}}